1 / 136

ANTIVIRAL/ANTIFUNGAL AGENTS

ANTIVIRAL/ANTIFUNGAL AGENTS. MA. LENY ALDA G. JUSAYAN, MD Department of Pharmacology. ANTIVIRAL AGENTS. VIRUSES: Single or double stranded DNA or RNA enclosed in a protein – CAPSID Obligate intracellular parasite Replication depends on synthetic processes of the host cell

ballari
Download Presentation

ANTIVIRAL/ANTIFUNGAL AGENTS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ANTIVIRAL/ANTIFUNGAL AGENTS MA. LENY ALDA G. JUSAYAN, MD Department of Pharmacology

  2. ANTIVIRAL AGENTS VIRUSES: • Single or double stranded DNA or RNA enclosed in a protein – CAPSID • Obligate intracellular parasite • Replication depends on synthetic processes of the host cell • Antiviral drugs must either block entry or exit from cell or be active inside the host cell

  3. VIRAL REPLICATION: • Adsorption and penetration into susceptible host cells • Uncoating of viral nucleic acid • Synthesis of early regulatory proteins • Synthesis of RNA or DNA • Synthesis of late regulatory proteins • Assembly (maturation) of viral particles • Release from cells

  4. ANTI-HERPES/ ANTI VZV

  5. ACYCLOVIR • Acyclovir (9-[2-hydroxy) methyl]-9-H- guanine • Acyclic guanosine derivative against HSV1, HSV2, & VZV • Weaker activity against EBV, CMV, Human Herpes Virus 6

  6. MECHANISM OF ACTION: • REQUIRES 3 PHOSPHORYLATION STEPS: • Converted to monophosphate derivative by virus-specified thymidine kinase • Converted to di and triphosphate compounds by the host’s cellular enzymes • Acyclovir triphosphate inhibits viral DNA synthesis

  7. Cont. • Acts as a chain terminator because it lacks 3’ hydroxyl group • Competitive inhibition of deoxyGTP for viral DNA polymerase RESISTANCE: • HSV: absence of partial production of viral thymidine kinase, altered thymidine kinase substrate specificity, altered viral DNA polymerase • VZV: mutation in VZV thymidine kinase , mutations in viral DNA polymerase

  8. PHARMACOKINETICS: • Oral bioavailability ranges from 10-30% and decreases with increasing dose • Relative oral bioavailability increases to 3-5 fold approx. 70% following valacyclovir administration • Distributes widely in body fluids including vesicular fluid, aqueous humor & CSF • Concentrated in breast milk, amniotic fluid, & placenta • Percutaneous absorption is low

  9. THERAPEUTIC USES: • First and recurrent genital herpes: • 200 mg 5x daily for 10 days – oral • 5 mg/kg per 8 hrs – IV • Recurrent: 400 mg 2x daily or 200 mg 3x daily

  10. THERAPEUTIC USES: • ACUTE HERPES ZOSTER (SHINGLES) • SYSTEMIC ACYCLOVIR PROPHYLAXIS • HSV ENCEPHALITIS • VARICELLA ZOSTER VIRUS INFECTION • CMV PROPHYLAXIS

  11. SIDE EFFECTS: • TOPICAL PREPARATIONS- mucosal irritation & transient burning to genital lesions • ORAL – nausea, diarrhea, rash, headache,renal insufficiency, neurotoxicity • IV- renal insufficiency, CNS side effects

  12. PENCICLOVIR • Penciclovir (9-[4-hydroxy-3-hydroxymethylbut-1-yl]guanine • An acyclic guanine nucleoside • Active metabolite of famciclovir • Spectrum of activity & potency against HSV & VZV is similar to acyclovir • Inhibitory activity to HBV

  13. MECHANISM OF ACTION: • Inhibitor of viral DNA synthesis • Initially phosphorylated by viral thymidine kinase • Penciclovir triphosphate is a competitive inhibitor of viral DNA polymerase • 100 fold less potent in inhibiting DNA polymerase than acyclovir but present in higher concentration and prolonged periods in infected cells

  14. THERAPEUTIC USES: • Intravenous form- 5 mg/kg per 8-12 hrs for 7 days is comparable to acyclovir in tx of mucocutaneous HSV infection • Topical 1% penciclovir cream applied every 2 hrs while awake for 4 days shortens healing time and symptoms by about 1 day in recurrent labial HSV

  15. SIDE EFFECTS: • Mutagenic at high concentrations • No clinically important drug interactions have identified

  16. FAMCICLOVIR • Diacetyl ester prodrug of 6 deoxy penciclovir and lacks intrinsic viral activity • Oral form is approved for managing HSV & VZV infections • First episode genital herpes – 250 mg TID x 5-10 days • Recurrent genital herpes – 250 mg BID for 1 year • Herpes zoster of 3 days – 500 mg TID x 10 days is as effective as acyclovir in reducing healing time and zoster asso. pain

  17. FAMCICLOVIR: • Comparable to valacyclovir in treating zoster and reducing associated pain in older adults • 500 mg TID x 10 days is comparable to high dose of acyclovir in treating zoster in immunocompromised patients & in opthalmic zoster • Associated with dose-related reductions in Hepatitis B Virus DNA and transaminase levels in patients with chronic HBV hepatitis

  18. TRIFLURIDINE • Flourinated pyrimidine nucleoside that has an in vitro inhibitory activity against HSV 1 & 2 , CMV, vaccinia certain adenoviruses • Inhibits viral DNA synthesis • Phosphorylated intracellularly into its active form by cellular enzymes • Incorporation into both viral and cellular DNA prevents its systemic use

  19. MECHANISM OF ACTION: • Trifluridine monophosphate irreversibly inhibits thymidylate synthetase • Trifluridine triphosphate is a competitive inhibitor of thymidine triphosphate incorporation into DNA by DNA polymerases

  20. CLINICAL USES: • Primary keratoconjunctivitis & recurrent epithelial keratitis due to HSV 1 & 2 • Topical trifluridine is more active than idoxuridine & comparable to vidarabine in HSV ocular infections

  21. ADVERSE EFFECTS: • Discomfort upon instillation • Palpebral edema • Hypersensensitivity reaction, irritations & superficial punctate or epithelial keratopathy

  22. VALACYCLOVIR • L- valyl ester of acyclovir • Rapidly converted to acyclovir after oral administration • Serum levels are 3-5x greater than acylcovir • Treatment of primary and recurrent genital herpes & herpes zoster infections • Prevents CMV disease in postransplant patients

  23. VIDARABINE • Adenosine analog with an in vitro activity against HSV, VZV, & CMV • Phosphorylated intracellularly by host enzymes to form ara-ATP and then inhibits viral DNA polymerase • Vidarabine triphosphate is incorporated into both vial & cellular DNA • Rapidly metabolized in vivo to hypoxanthine arabinoside through removal of 6-amino group by adenosine deaminase – dec. viral activity

  24. Cont. • 3% ointment – acute keratoconjunctivitis, superficial keratitis, recurrent epithelial keratitis (HSV1 &2) • IV vidarabine – HSV encephalitis,neonatal herpes, VZV infection

  25. ANTI-CMV AGENTS

  26. GANCICLOVIR • (9-[1,3-dihydroxy-2-prpoxymethyl]guanine) • Cyclic guanosine analog that requires triphosphorylation for activation prior to inhibiting viral DNA polymerase • Similar structure to acyclovir except in having additional hydroxymethyl group on the acyclic side chain

  27. MECHANISM OF ACTION: • Monophosphorylated intracellularly by a virus-induced enzyme • Phosphorylation is catalyzed by a viral thymidine kinase during HSV, phosphotransferase encoded gene during CMV infection • Ganciclovir di & triphosphate formed by cellular enzymes • Triphosphate is a competitive inhibitor of deoxyguanosine triphosphate incorporation into DNA, inhibits viral rather than cellular DNA polymerase • Viral DNA incorporation causes cessation of DNA chain elongation

  28. PHARMACOKINETICS: • Oral bioavailability is 6-9% following ingestion with food & less in the fasting state • CSF concentration are approximately 50 % of those in serum

  29. CLINICAL USES: • Delay progression of CMV retinitis in AIDS • CMV colitis & esophagitis • CMV infection in transplant patient • CMV pneumonitis • CMV retinitis • CMV, HSV1, HSV2, EBV & HHV-8

  30. ADVERSE REACTIONS: • Myelosuppression • CNS toxicity • Vitreous hemorrhage, retinal detachment • Neutropenia (2nd wk) • CNS (headache, behavioral changes, convulsions, coma) • Infusion related phlebitis, azotemia, anemia, rash, fever, liver function test abnormalities

  31. VALGANCICLCOVIR • L- valyl ester prodrug of ganciclovir • Hydrolyzed to active compound ganciclovir by intestinal & hepatic enzymes • Well absorbed & rapidly metabolized in intestinal walls & liver to gancilovir • CMV retinitis

  32. CIDOFOVIR • (1-[(S)-3-hydroxy-2-(phosphonomethoxy)-propyl]cytosine dihydrate) • Cytidine nucleoside analog with inhibitory activity against human herpes, papiloma, polyoma, pox, & adenoviruses • Phosphorylation to active diphosphate is independent of viral enzymes • After phosphorylation it acts as potent inhibitor to viral DNA polymerase

  33. PHARMACOKINETICS: • Penetration into the CNS or eye have not been well characterized • Terminal half-life is 2.6 hrs , cidofovir diphosphate half-life is 17-65 hrs • IV administration must be administered with probenicid to block active tubular secretion & decrease nephrotoxicity

  34. CLINICAL USES: • CMV, HSV 1, HSV 2, VZV, EBV, HHV-6, HHV-8, adenoviruses, poxvirus, poliomyxoviruses, HPV • CMV retinitis • Polyoma virus associated progressive multifocal leukoencephalopathy syndrome associated with AIDS • Topical – recurrent genital herpes, anogenital warts

  35. FOSCARNET • Phosphonoformic acidinorganic pyrophosphate analog that inhibits viral DNA polymerase, RNA polymerase & HIV transcriptase directly without requiring activation by phosphorylation • Taken up slowly by cells & does not undergo significant intracellular metabolism • Reversibly blocks the pyrophosphate binding site of the viral polymerase • Inhibits cleavage of pyrophosphate from deoxynucleotide triphosphates

  36. SIDE EFFECTS: • Nephrotoxicity • Symptomatic hypocalcemia • Saline loading may reduce the risk of nephrotoxicity • Concurrent administration with pentamidine exacerbates both nephrotoxicity & hypocalcemia

  37. CLINICAL USES: • CMV retinitis, colitis, esophagitis • Acyclovir- resistant HSV infection & VZV infection • HSV, VZV, CMV, EBV, HHV-6, HHV-8, HIV

  38. FOMIVERSEN • 21mer-phosphorothioate oligonucleotide • First FDA approved antisense therapy Binding to target mRNA results in inhibiton of immediate early region 2 protein synthesis – inhibiting viral replication • Injected intravitreally in CMV retinitis

  39. ANTIVIRAL DRUGS – DNA & RNA VIRUSES

  40. ANTIRETROVIRAL AGENTS

  41. NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS: • Competitive inhibition of HIV 1 reverse transcriptase & can be incorporated into the growing viral DNA chain to cause termination • Bind directly to HIV reverse transcriptase, block both DNA & RNA dependent DNA polymerase activities • Prevent transfer of information that would allow virus to replicate & survive • Activity against HIV 1, HIV 2 • Lactic acidosis & severe hepatomegaly with steatosis

  42. ZIDOVUDINE (Azithymidine, AZT) • Deoxythymidine analog • Decrease rate of clinical disease progression & prolong survival of HIV infected individuals • Well absorbed from the gut & distributed to most body tissues & fluids • Eliminated by renal excretion following glucorinadation in the liver • Combination therapy with other retroviral agents enhance potency and delay resistance

  43. CLINICAL USES: • HIV – associated dementia & thrombocytopenia • Reduce rate of vertical transmission (mother-newborn) by 23%

  44. ADVERSE EFFECTS: • Myelosuppression – most common • Thrombocytopenia, hyperpigmentation of nails, myopathy, anxiety, confusion & tremulousness • Fatal lactic acidosis & severe hepatomegaly w/ steatosis

  45. DIDANOSINE (ddl) • Synthetic analog of deoxyadenosine • Activity is potentiated by hydroxyurea due to depletion of intraocular pools of dATP • Chewable, dispersable tablet, enteric coated • Contains phenylalanine & Na • Should be taken on an empty stomach • Food, fluroquinolones & tetracycline should be given 2 hrs before didanosine

  46. ADVERSE EFFECTS: • Dose –dependent pancreatitis • Painful peripheral distal neuropathy • Diarrhea, hepatitis, esophageal ulceration, cardiomyopathy • CNS toxicity • Precipitate gouty attacks • Optic neuritis

  47. LAMIVUDINE (3TC) • Cytosine analog ,synergistic with other antiretroviral nucleoside – Stavudine, Zidovudine • Oral bioavailability exceeds 80% & is not food dependent • Used in combination therapy • Approved for the treatment of chronic Hepatitis B infection

More Related